Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.07.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Sagar Lonial und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address: sloni@emory.ed…. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Janssen Pharmaceuticals.
Abstract (Originalsprache)
INTRODUCTION: Multiple myeloma is a hematologic malignancy that is typically associated with recurrent relapses. There are numerous frontline treatment regimens that are highly effective for individual patients. The introduction of anti-CD38 monoclonal antibody therapy has shifted treatment decision-making in this setting, with many centers now considering the use of daratumumab as part of initial therapy regardless of patient eligibility for autologous stem cell transplantation (ASCT). Daratumumab has demonstrated clinical efficacy and acceptable toxicity in the first and later lines of therapy, increasing complexity in treatment selection and sequencing. Although daratumumab-containing regimens may not be appropriate for every patient, it is increasingly recognized that the most effective regimens should be used upfront, as high rates of attrition mean that many patients in real-world practice may see a limited number of lines of therapy. METHODS: A panel of experts in multiple myeloma was convened to consider current evidence and treatment practices to inform a series of consensus statements on the optimal management of newly diagnosed multiple myeloma, including not only treatment selection, but the need for infection prophylaxis, route of administration, and mitigation of potential infusion-related reactions, among other clinical challenges. RESULTS/CONCLUSIONS: The goal of the present review article is to encapsulate these consensus statements and the rationale for their development, which altogether may help inform treatment selection and clinical decision-making in the front line.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. Electronic address: sloni@emory.edu.
- IconCME, Philadelphia, PA.
- Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029-5674, USA.
- Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, California, USA.
- Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Förderung
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
Zitieren
APA
Lonial, S., Bowser, A. D., Chari, A., Costello, C., Krishnan, A., & Usmani, S. Z. (2023). Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.07.001
Vancouver
Lonial S, Bowser AD, Chari A, Costello C, Krishnan A, Usmani SZ. Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.07.001
BibTeX
@article{Lonial2023,
author = {Lonial, Sagar and Bowser, Andrew D and Chari, Ajai and Costello, Caitlin and Krishnan, Amrita and Usmani, Saad Z},
title = {Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.07.001}
}
EUVIMED